Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 10, 2016 (10 years ago)

Tazorac (tazarotene)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Content Uniformity Specifications.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g, sample packs, Allergan Inc, Irvine, CA 92612. UPC 300238335159

Drug: Tazarotene

Recalling firm
Allergan Sales, LLC
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1065-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tazarotene recalls

See all
Class III · Low risk

Fabior (tazarotene)

Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

Terminated Wrong potency / content Mayne Pharma Inc NDC 51862-295-10 D-0616-2018

Other recalls by Allergan Sales, LLC

All 2016 recalls
Class II · Moderate risk

Blephamide

Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.

Terminated Impurity / degradation Allergan Sales, LLC D-0929-2017